Cancer cell progression and chemoimmunotherapy- dual effects in the induction of resistance to therapy
1996

Cancer Cell Progression and Chemoimmunotherapy

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): J Hamuro, T Kikuchi, F Takatsuki, M Suzuki

Primary Institution: Basic Research Laboratories, Central Research Laboratories, Ajinomoto Co.

Hypothesis

Does resistance to chemoimmunotherapy occur during therapy?

Conclusion

The study found that the production of prostaglandin E2 (PGE2) in progressed tumor lines increased during therapy, contributing to the acquisition of resistance to treatment.

Supporting Evidence

  • Nearly all treated mice achieved complete tumor regression.
  • Only a few mice showed tumor recurrence in regional lymph nodes.
  • Combination therapy with lentinan and IL-2 achieved complete tumor regression in progressed tumor lines.

Takeaway

The study shows that some cancer cells can become resistant to treatment over time, making it harder to cure the disease.

Methodology

Mice were treated with cyclophosphamide and lentinan, and tumor growth was measured to evaluate the effectiveness of the treatment.

Limitations

The study primarily focused on a specific type of tumor in mice, which may not fully represent human cancer.

Participant Demographics

Normal female mice, 6-10 weeks of age.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication